Numerous scientific reports and publications related to FGF-1141 have been authored by our scientific staff and their colleagues. Many are available online. For those that aren’t available, please contact us to receive a copy.

Schumacher B, Pecher P, von Specht BU, Stegmann TJ. Induction of neoangiogenesis in ischemic myocardium by human growth factors. First clinical results of a new treatment of coronary heart disease. Circulation 97: 645-650 (1998)

Stegmann TJ. FGF1: A human growth factor in the induction of neoangiogenesis. Exp. Opin. Invest. Drugs 7: 2011-2015 (1998)

Schumacher B, Stegmann TJ, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: First clinical results. J. Cardiovasc. Surg. 39: 783-789 (1998)

Stegmann TJ. New approaches to coronary heart disease. Induction of neovascularization by growth factors. BioDrugs 11: 301-308 (1999)

Stegmann TJ, Hoppert T. Combined local angiogenesis and surgical revascularization for coronary heart disease. Current Intervent. Cardiol. Reports 1: 172-178 (1999).

Stegmann TJ. Intramyocardial injection of acidic fibroblast growth factor: adjunct to bypass surgery and monotherapy for coronary heart disease. In: Handbook of Myocardial Revascularization and Angiogenesis, ed. by R. Kornosky, S.E. Epstein, M. Leon. M. Dunitz Ltd., London, 1999, p. 201-214

Stegmann TJ. Myocardial Neo-Angiogenesis by Local Application of Growth Factors. In: XXI Congress of the Europ. Soc. Cardiology, ed. by F. Navarro-Lopez. Monduzzi Editore, Internat. Proceedings Division, Bologna, Italy, 1999, p.319-322

Stegmann TJ, Hoppert T, Schlurmann W, Gemeinhardt S. First angiogenic treatment of coronary heart disease by FGF1: Long term results after 3 years. Cardiac and Vascular Regeneration 1: 5-10 (2000)

Stegmann TJ, Hoppert T: Gentherapie bei kardiovaskulären Erkrankungen. J. Kardiol. 7: 292-295 (2000)

Stegmann TJ, Hoppert T, Schneider A, Gemeinhardt S, Köcher M, Ibing R, Strupp G. Induktion der myokardialen Neoangiogenese durch humane Wachstumsfaktoren. Ein neuer Therapieansatz bei koronarer Herzkrankheit. Herz 25: 589-599 (2000)

Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in angiogenesis: issues, problems, consensus. Circulation 102: e73-386 (2000)

Thomas J.Stegmann, M.D., Thomas Hoppert, M.D., Andre Schneider, M.D., Michael Popp, M.D., Gerhard Strupp, M.D., Rainer o. Ibing, M.D., and Andreas Hertel, M.D. Therapeutic Angiogenesis: Cardiac and Vascular Regeneration Vol. 1, No. 4. Dec: 259-267 (2000)

Wagoner LE, Snavely D, Conway GA, Hauntz EA, Merrill W. Intramyocardial injection of fibroblast growth factor-1 for refractory angina pectoris: The initial US experience. Circulation 110, Suppl. III: 395 (2004)

Stegmann TJ. Protein Therapy vs. Gene Therapy, Drug Discovery News. 13 December 2006: p. 9.

Stegmann TJ. Protein Promise in Heart Disease. Good Clinical Practices Journal. March 2007: p. 22-24.

Jacobs, J. A Renewed Emphasis on Therapeutic Angiogenesis Research for CAD. Biotechnology Healthcare. October 2007: pg. 49 -54.

Jacobs, J. Combating cardiovascular disease with angiogenic therapy. Drug Discovery Today. Vol. 12, Nos. 23/24. Dec:1040 – 1045 (2007).

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.